A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

2019147 citationsJournal Article

Authors

Toshihiko Doi · National Cancer Center Hospital East

Kei Muro · Aichi Cancer Center

Hiroshi Ishii · Shikoku Cancer Center

Terufumi Kato · Kanagawa Prefectural Hospital Organization

Takahiro Tsushima · Shizuoka Cancer Center

Mitsuhiro Takenoyama · National Hospital Organization Kyushu Cancer Center

Satoshi Oizumi

Abstract

Combining an anti-PD-1 antibody, nivolumab, with a Treg-depleting anti-CCR4 antibody, mogamulizumab, provides an acceptable safety profile, antitumor activity, and a potentially effective option in cancer immunotherapy.

Topics & Keywords

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 22, pp. 6614-6622

DOI: 10.1158/1078-0432.ccr-19-1090

Field-Weighted Citation Impact: 8.67